Trial Profile
A Double-blind, Randomised, Placebo- and Active-controlled, Cross-over Study to Investigate the Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Nebicapone (Primary) ; Entacapone
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
- 19 Jul 2016 New trial record